首页> 美国卫生研究院文献>other >In vivo Interactions between α7 Nicotinic Acetylcholine Receptor and Nuclear Peroxisome Proliferator-Activated Receptor-α: Implication for Nicotine Dependence
【2h】

In vivo Interactions between α7 Nicotinic Acetylcholine Receptor and Nuclear Peroxisome Proliferator-Activated Receptor-α: Implication for Nicotine Dependence

机译:α7烟碱乙酰胆碱受体和核过氧化物酶体增殖物激活受体-α之间的体内相互作用:对尼古丁依赖性的影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic tobacco use dramatically increases health burdens and financial costs. Limitations of current smoking cessation therapies indicate the need for improved molecular targets. The main addictive component of tobacco, nicotine, exerts its dependency effects via nicotinic acetylcholine receptors (nAChRs). Activation of the homomeric α7 nAChR reduces nicotine's rewarding properties in conditioned place preference (CPP) test and i.v. self-administration models, but the mechanism underlying these effects is unknown. Recently, the nuclear receptor peroxisome proliferator-activated receptor type-α (PPARα) has been implicated as a downstream signaling target of the α7 nAChR in ventral tegmental area dopamine cells. The present study investigated PPARα as a possible mediator of the effect of α7 nAChR activation in nicotine dependence. Our results demonstrate the PPARα antagonist GW6471 blocks actions of the α7 nAChR agonist PNU282987 on nicotine reward in an unbiased CPP test in male ICR adult mice. These findings suggests that α7 nAChR activation attenuates nicotine CPP in a PPARα-dependent manner. To evaluate PPARα activation in nicotine dependence we used the selective and potent PPARα agonist, WY-14643 and the clinically used PPARα activator, fenofibrate, in nicotine CPP and we observed attenuation of nicotine preference, but fenofibrate was less potent. We also studied PPARα in nicotine dependence by evaluating its activation in nicotine withdrawal. WY-14643 reversed nicotine withdrawal signs whereas fenofibrate had modest efficacy. This suggests that PPARα plays a role in nicotine reward and withdrawal and that further studies are warranted to elucidate its function in mediating the effects of α7 nAChRs in nicotine dependence.
机译:长期使用烟草会大大增加健康负担和财务成本。当前戒烟疗法的局限性表明需要改进的分子靶标。烟草的主要成瘾成分尼古丁通过烟碱乙酰胆碱受体(nAChRs)发挥其依赖性作用。同源α7nAChR的激活降低了条件位置偏好(CPP)测试和i.v.中尼古丁的奖励特性。自我管理模型,但这些作用的潜在机制尚不清楚。近年来,核受体过氧化物酶体增殖物激活受体-α(PPARα)被认为是腹侧被盖区多巴胺细胞中α7nAChR的下游信号传导靶。本研究调查了PPARα作为烟碱依赖性α7nAChR激活作用的可能介体。我们的结果证明,在雄性ICR成年小鼠的无偏CPP测试中,PPARα拮抗剂GW6471阻止了α7nAChR激动剂PNU282987对尼古丁奖赏的作用。这些发现表明,α7nAChR激活以PPARα依赖性方式减弱了尼古丁CPP。为了评估尼古丁依赖性中的PPARα活化作用,我们在尼古丁CPP中使用了选择性有效的PPARα激动剂WY-14643和临床使用的PPARα活化剂非诺贝特,并观察到尼古丁偏好减弱,但非诺贝特的效价较低。我们还通过评估尼古丁戒断中的激活来研究尼古丁依赖性中的PPARα。 WY-14643可以逆转尼古丁戒断症状,​​而非诺贝特的疗效中等。这表明PPARα在尼古丁的奖励和戒断中起作用,并且有必要进一步研究阐明其在介导α7nAChRs对尼古丁依赖性的影响中的功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号